Business contacts – Page 6

Coronavirus Patents: China Files for Remdesivir Patent, but Gilead Sciences Will Still Come Out a Winner

On February 4, the Wuhan Institute of Virology announced that it had applied for a Chinese patent on Gilead’s Remdesivir for novel coronavirus treatment in order to protect the national interests of China. <ClickHere>

Medical supply chains are fragile in the best of times and COVID-19 will test their strength

The COVID-19 pandemic has brought medical supply chains into the spotlight. <ClickHere>

Will governments override patent rights in the race to find a cure for COVID-19?

The outbreak of COVID-19 coronavirus has prompted a global race to find a vaccine to fight the disease. <ClickHere>

“Playing Both Sides?” Branded Sales, Generic Sales and Patent Policy

In this article, we explore a phenomenon we call “playing both sides”: companies that participate in pharmaceutical markets as both brand owners and generics. We hypothesize that companies that earn a significant amount of their revenue from patented drugs may have less incentive to aggressively pursue a generic agenda, since patented drugs generate far more revenue for firms than generic drugs do. <ClickHere>

Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines

Gloomy predictions about the future of pharma have forced the industry to investigate alternative models of drug discovery. Public-private partnerships (PPPs) have the potential to revitalize the discovery and development of first-in-class therapeutics. <ClickHere>

Drug Patent Expirations and the “Patent Cliff”

Beginning in 2010, the pharmaceutical industry faced one of the biggest waves of drug patent expirations in history, a phenomenon referred to as the “patent cliff.” <ClickHere>

The Structural Changes in the Global Pharmaceutical Marketplace and Their Possible Implications for Intellectual Property

A number of changes have taken place in the global pharmaceutical marketplace over the last decade that are putting pressure on the large research and development (R&D)-based pharmaceutical transnational corporations (TNCs) to change the way they do business.<ClickHere>

Category: Business contacts